On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP
On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP
This Week in Asia /  Politics

India aims to use coronavirus ‘vaccine diplomacy’ to counter China, but is it jumping the gun?

  • India aims to roll out its Covid-19 vaccines Covishield and Covaxin to its neighbours to boost its regional importance
  • But analysts say New Delhi must tread cautiously as Covaxin has not completed phase three trials and any side effects could cause a diplomatic crisis

Topic |   Coronavirus pandemic
Vasudevan Sridharan
Vasudevan Sridharan

Updated: 3:47pm, 9 Jan, 2021

Why you can trust SCMP
On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP
On January 3, India’s drug regulator authorised two vaccines for emergency use – Covishield and Covaxin, a home-grown vaccine by the Hyderabad-based giant Bharat Biotech which has not yet completed human trials. Photo: AP
READ FULL ARTICLE